arrow
A

Abhishek A. Mangaonkar

Mayo Clinic
H指数:30
被引数:3,408

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Long-term survival outcomes after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for relapsed/refractory metastatic germ cell tumors: contemporary Mayo Clinic experience

高剂量化疗联合自体造血干细胞移植治疗复发/难治性转移性生殖细胞肿瘤的长期生存结局:当代梅奥诊所经验

2026-10-290
PRE
Prognostic impact of need for re-induction based on day-14 residual disease and age-adapted consolidation strategy in acute myeloid leukemia

基于第14天残留病灶和年龄适应巩固策略的再诱导需求对急性髓系白血病预后的影响

2026-09-300
OAAI
Clinical and molecular characteristics of clonal monocytosis with and without cytopenia(s)

克隆性单核细胞增多症的临床和分子特征:伴有与不伴有血细胞减少(症)的比较

Leukemia
IF13.4
2026-09-280
PRE
Evaluating the Efficacy of Cytokine-Directed Therapies in the Management of VEXAS Syndrome

评估细胞因子导向疗法在VEXAS综合征管理中的疗效

2026-09-250
OAAI
Venetoclax Plus Hypomethylating Agent for 7- Versus 14- Versus 21- Versus 28-Day Cycles in Newly-Diagnosed Acute Myeloid Leukemia: ELN and Mayo Genetic Risk–Stratified Analysis in 540 Patients

维奈克拉联合去甲基化药物用于新诊断急性髓系白血病7天、14天、21天及28天疗程:基于ELN和Mayo遗传风险分层的540例患者分析

2026-09-180
PRE
Coronary Artery Calcification as a Predictor of Survival in Patients Receiving Post-transplant Cyclophosphamide for GVHD Prophylaxis

冠状动脉钙化作为接受移植后环磷酰胺预防GVHD患者的生存预测因子

2026-09-012
OAAI
Determinants of survival after failure of frontline venetoclax plus hypomethylating agent therapy in 356 patients with newly diagnosed acute myeloid leukemia

356例新诊断急性髓系白血病患者一线维奈克拉联合去甲基化药物治疗失败后的生存影响因素

2026-08-170
OAAI
Risk-Adjusted Comparison of Survival in Chronic Myelomonocytic Leukemia With and Without Allogeneic Stem Cell Transplant: Mayo Clinic Experience in 775 Consecutive Patients

慢性髓系单核细胞白血病患者行异基因干细胞移植与未移植者的风险调整生存比较:梅奥诊所775例连续患者的经验

2026-07-280
PRE
Promoter TERT-Related Hematopoietic Somatic Mosaicism in Patients With Telomere Biology Disorders

端粒生物学障碍患者中与TERT启动子相关的造血体细胞嵌合现象

2026-07-280
OAAI
Characteristics and outcomes of secondary hematological malignancies following autologous stem cell transplantation for multiple myeloma

自体干细胞移植治疗多发性骨髓瘤后继发血液系统恶性肿瘤的特征与结局

2026-06-230
OAAI
Extended Cancer Spectrum in Adults With Telomere Biology Disorders: Insights From a 113-Patient Single-Center Cohort

端粒生物学障碍成人患者中扩展的癌症谱:来自113例患者单中心队列的见解

2026-06-220
OAAI
Inherited DNA repair variants are associated with clonal hematopoiesis and cardiovascular risk in men with metastatic prostate cancer

携带转移性前列腺癌男性中,遗传性DNA修复变异与克隆性造血和心血管风险相关

2026-05-010
OA
CMML2AML: machine-learning discovery of co-mutations and specific single mutations predictive of blast transformation in chronic myelomonocytic leukemia

CMML2AML:机器学习发现与慢性骨髓单核细胞白血病blast transformation相关的共突变和特异性单突变

2026-04-120
OAAI
CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients

CPX-351(脂质体阿糖胞苷和柔红霉素)与维奈克拉联合表观遗传药物疗法在初诊急性髓系白血病中的比较:一项涉及600例梅奥诊所患者的回顾性比较研究

2026-04-060
OAAI